about
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agentsTargeted probes for cardiovascular MRIGadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.Assessing renal function in children with hydronephrosis - additional feature of MR urographyNephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancementIs administration of gadolinium-based contrast media to pregnant women and small children justified?Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.Novel Mn3 [Co(CN)6]2@SiO2@Ag Core-Shell Nanocube: Enhanced Two-Photon Fluorescence and Magnetic Resonance Dual-Modal Imaging-Guided Photothermal and Chemo-therapy.Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.Gadolinium inhibits prostate cancer PC3 cell migration and suppresses osteoclast differentiation in vitro.European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.NSF after Gadovist exposure: a case report and hypothesis of NSF development.Radiographic and magnetic resonances contrast agents: Essentials and tips for safe practices.Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
P2860
Q33403791-A89A14B3-B937-4B9E-83A9-7E2B5193958FQ33901726-DC8182D5-A17A-4AA0-816E-C033574D725DQ35927046-A1159ACB-85A1-4980-A627-A3156A3666DCQ36177820-9363EE61-FA9A-4E4A-92DA-0F23986FA66AQ36324674-3BE3765B-B926-42A1-892D-5BE430A2EE46Q37152523-DA9D4ACA-7AEC-4AB7-A632-4C81DAC45031Q37934729-BC3BDBBA-A7F7-4F89-B08D-E1309C008D69Q38032230-6F4665D3-254D-41B1-8368-8EC0465F5DA0Q38830260-701141A7-61E6-457D-ACF7-F694802355FEQ39437352-15E68E39-8DF0-4BCB-9700-AE89F6EB74A5Q39538019-84809302-0D1F-438B-AFE5-B2151BCD0C95Q40102390-B18B5B75-9F44-4898-B0D8-B9C16D3F848AQ41991927-79601984-748E-4533-8447-BE88A69FD392Q43273904-7F1FC2EA-A57B-4EE8-A33F-FF4BE51F5F5FQ46463175-558FE823-3237-4FEB-AE9E-AFDCDC920438Q50999837-46EE25AA-19EE-461D-A48B-B9BC657E0524Q55515077-524DC7CC-D0E1-404E-ABA5-37946C4BFD3E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Extracellular Gd-CA: differences in prevalence of NSF.
@en
Extracellular Gd-CA: differences in prevalence of NSF.
@nl
type
label
Extracellular Gd-CA: differences in prevalence of NSF.
@en
Extracellular Gd-CA: differences in prevalence of NSF.
@nl
prefLabel
Extracellular Gd-CA: differences in prevalence of NSF.
@en
Extracellular Gd-CA: differences in prevalence of NSF.
@nl
P1476
Extracellular Gd-CA: differences in prevalence of NSF.
@en
P2093
Henrik S Thomsen
Peter Marckmann
P304
P356
10.1016/J.EJRAD.2008.01.024
P577
2008-03-14T00:00:00Z